• MannKind flagged new clinical analyses on Furoscix ReadyFlow, with results presented at HFSA 2026 on Oct. 9-12.
• Studies indicated the autoinjector delivered diuretic effects comparable to intravenous furosemide, supporting outpatient treatment of fluid overload.
• Data also supported flexible injection-site use without loss of performance, easing real-world administration.
• Cross-study findings suggested similar responses versus the older Furoscix on-body infusor, supporting a transition to the newer device.
• The update follows FDA clearance in July 2026 and a U.S. launch positioning ReadyFlow as an IV-equivalent, rapid-delivery option.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610092000PRIMZONEFULLFEED9841965) on October 10, 2026, and is solely responsible for the information contained therein.